Article
Biochemistry & Molecular Biology
Sudath Hapuarachchige, Ge Si, Colin T. Huang, Wojciech G. Lesniak, Ronnie C. Mease, Xin Guo, Kathleen Gabrielson, Dmitri Artemov
Summary: Pretargeted drug delivery using a HER2 pretargeting component and a drug delivery component showed significant therapeutic efficacy in a HER2-positive breast cancer model, demonstrating a promising approach for cancer therapy.
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David A. Cameron
Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, Denai R. Milton, Angelica M. Gutierrez, Stephen K. Gruschkus, John E. Lewis, Rashmi K. Murthy, Banu K. Arun
Summary: BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)-positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu-positive breast cancer.
Review
Oncology
Erika Hamilton, Mythili Shastry, S. Michelle Shiller, Rongqin Ren
Summary: The heterogeneity of HER2 expression in breast cancer is being recognized as an important factor that impacts treatment outcomes, with the development of novel therapies to target tumors with non-uniform HER2 expression.
CANCER TREATMENT REVIEWS
(2021)
Article
Cell Biology
Yujing Li, Yifan Sun, Michael Kulke, Torsten Hechler, Kevin Van der Jeught, Tianhan Dong, Bin He, Kathy D. Miller, Milan Radovich, Bryan P. Schneider, Andreas Pahl, Xinna Zhang, Xiongbin Lu
Summary: The heterozygous loss of chromosome 17p, a common genomic event in breast cancer, leads to global gene expression changes, reduced T cell tumor infiltration, and deletion of tumor suppressor genes like TP53. This loss also makes breast cancer cells sensitive to POLR2A inhibition, enabling targeted precision immunotherapy.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Lisa Gruentkemeier, Aditi Khurana, Farideh Zamaniyan Bischoff, Oliver Hoffmann, Rainer Kimmig, Mathew Moore, Philip Cotter, Sabine Kasimir-Bauer
Summary: The study utilized the DEPArray(TM) system for HER2/FISH analysis, which can identify HER2/FISH discordance in BC patients, aiding in determining the need for anti-HER2 therapy.
Review
Biochemistry & Molecular Biology
Pinchao Fan, Kun Xu
Summary: In the past decade, antibody-drug conjugates (ADCs) have made considerable progress in the treatment of solid tumors, including breast cancer. ADCs combine the specificity of monoclonal antibodies and the potency of cytotoxic drugs, allowing targeted delivery of cytotoxic agents to tumor cells with heterogeneous antigen expression. Three ADCs (T-DM1, T-DXd, and SG) have been approved for clinical use in breast cancer, with many promising products in development. ADCs have revolutionized the treatment paradigm for HER2-low breast cancer, which was previously considered lacking definitive targets and effective regimens. This article discusses the current knowledge, recent advancements, and future perspectives of ADCs in HER2-overexpressing and HER2-low breast cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Review
Medicine, General & Internal
Klaudia Katarzyna Brogowska, Monika Zajkowska, Barbara Mroczko
Summary: Breast cancer is the most common and lethal malignancy in women. Its development is influenced by factors such as age, genetic mutations, and body weight. Currently, there is a lack of sensitive and specific screening tests, but researchers are exploring new diagnostic biomarkers. The VEGF family of proteins and their receptors play a significant role in the pathogenesis of breast cancer and could potentially be used as diagnostic biomarkers and therapeutic targets.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O'Doherty, Wenhua Huang, Jinhua Zhao
Summary: Accurate determination of HER2 expression is crucial for HER2-targeted therapy. A novel Tc-99m-labeled anti-HER2 single-domain antibody was developed for noninvasive detection, showing safety, favorable biodistribution, and reasonable radiation doses in breast cancer patients. Tc-99m-NM-02 SPECT imaging may offer an accurate and noninvasive method for detecting HER2 status.
MOLECULAR PHARMACEUTICS
(2021)
Review
Medicine, General & Internal
Lixi Li, Di Zhang, Binliang Liu, Dan Lv, Jingtong Zhai, Xiuwen Guan, Zongbi Yi, Fei Ma
Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs, and have shown potential as a promising treatment option for breast cancer and other tumors.
CHINESE MEDICAL JOURNAL
(2022)
Review
Oncology
Martina Di Modica, Valeria Arlotta, Lucia Sfondrini, Elda Tagliabue, Tiziana Triulzi
Summary: Microbiota plays a key role in cancer by influencing various host physiological functions and affecting the efficacy of anticancer treatments. The involvement of the breast microbiota in breast cancer has been extensively studied. This review focuses on the impact of gut and breast microbiota on HER2+ breast cancer subtype and discusses the potential of defining microbial signatures associated with disease aggressiveness, treatment response, and therapy toxicity. The mechanisms of microorganism-host interactions and the possibility of microbiota editing in breast cancer prevention and treatment optimization are also explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Xueying Wan, Shengdong Guan, Yixuan Hou, Yilu Qin, Huan Zeng, Liping Yang, Yina Qiao, Shuiqing Liu, Qiao Li, Ting Jin, Yuxiang Qiu, Manran Liu
Summary: The FOSL2/Wnt5a signaling axis plays a crucial role in breast cancer angiogenesis in a VEGF-independent manner, and targeting this axis in cancer-associated fibroblasts may offer a potential option for anti-angiogenesis therapy.
Article
Pharmacology & Pharmacy
Adhika Balgobind, Aliscia Daniels, Mario Ariatti, Moganavelli Singh
Summary: This study assessed the efficacy of cationic lipid-based systems for the delivery of HER2/neu siRNA in breast cancer. The results showed that cationic liposomes efficiently bound, compacted, and protected the therapeutic siRNA against degradation. The non-PEGylated Chol-T-siRNA lipoplexes exhibited the highest HER2/neu silencing.
Article
Biochemistry & Molecular Biology
Mozafar Mohammadi, Foroogh Nejatollahi, Younes Ghasemi, Sayyid Nooreddin Faraji
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
(2017)
Article
Medicine, Research & Experimental
Vahid Bagheri, Foroogh Nejatollahi, Seyed Alireza Esmaeili, Amir Abbas Momtazi, Mohamad Motamedifar, Amirhossein Sahebkar
Article
Veterinary Sciences
Reza Valadan, Foroogh Nejatollahi, Hoda Ehsani-nori, Hassan Habibi, Hamid Amini, Mansour Aliabadian
Article
Oncology
Neda Zarei, Mehdi Fazeli, Mozafar Mohammadi, Foroogh Nejatollahi
BREAST CANCER RESEARCH AND TREATMENT
(2018)
Article
Gastroenterology & Hepatology
Seyed Hedayat Hosseini Khorami, Foroogh Nejatollahi, Mohammad Ali Davarpanah
Article
Oncology
Seyed-Alireza Esmaeili, Foroogh Nejatollahi, Amirhossein Sahebkar
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2018)
Article
Immunology
Seyed Nooreddin Faraji, Foroogh Nejatollahi, Ali-Mohammad Tamaddon, Mozafar Mohammadi, Ali Reza Aminsharifi
INTERNATIONAL IMMUNOPHARMACOLOGY
(2019)
Article
Medicine, Research & Experimental
Samaneh Alizadeh, Setareh Moazen, Seyed Nooreddin Faraji, Afagh Moattari, Foroogh Nejatollahi
Summary: In this study, human single-chain variable fragments (scFvs) targeting highly conserved epitopes in the hemagglutinin (HA) of influenza A viruses were selected and evaluated for their neutralizing activity. Four specific anti-HA scFvs were found to effectively neutralize different subtypes of influenza A virus with high reductions in virus titers and numbers. These results suggest that the selected anti-HA scFvs have the potential for universal therapy against influenza viruses.
IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Forough Abdollahzadeh, Foroogh Nejatollahi
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Mahboubeh Poursiyami, Foroogh Nejatollahi, Afagh Moatari
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Mohammad Javad Aghaei Afshar, Reza Robati, Foroogh Nejatollahi
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2019)
Review
Materials Science, Biomaterials
Ghazal Farahavar, Samira Sadat Abolmaali, Nasser Gholijani, Foroogh Nejatollahi
BIOMATERIALS SCIENCE
(2019)
Article
Biochemistry & Molecular Biology
Bahareh Moazen, Amir Zarrinhaghighi, Foroogh Nejatollahi
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Farideh Hosseinzadeh, S. Saeed Mohammadi, Foroogh Nejatollahi
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2017)
Article
Oncology
S. Saeed Mohammadi, Farideh Hosseinzadeh, Foroogh Nejatollahi
IRANIAN JOURNAL OF CANCER PREVENTION
(2017)